It wasn't only biopharma equities that suffered during the year. Going public also posed a challenge for companies. While the final count of 31 newly minted U.S. public biopharmaceutical companies sounds a respectable number for the year, we have come to expect much more based on statistics compiled by BioWorld. For example, a total of 54 companies successfully graduated to the public arena in 2015, collectively generating almost $5 billion, twice the amount generated by this year's crop of graduates. Read More
